Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Uncovering structural determinants of peptide recognition by public and private T-cell receptors.
Journal: bioRxiv : the preprint server for biology
Published: December 15, 2025
Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies.
Journal: Journal of gastroenterology and hepatology
Published: May 20, 2025
Long-persisting SARS-CoV-2 spike-specific CD4+ T cells associated with mild disease and increased cytotoxicity post COVID-19.
Journal: Nature communications
Published: April 28, 2025
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.
Journal: The lancet. Gastroenterology & hepatology
Published: October 23, 2024
T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination.
Journal: Nature communications
Published: June 19, 2024
HLA-E-restricted SARS-CoV-2-specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation.
Journal: Science immunology
Published: June 30, 2023
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Journal: Alimentary pharmacology & therapeutics
Published: May 18, 2023
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Journal: The lancet. Gastroenterology & hepatology
Published: April 14, 2023
Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection.
Journal: iScience
Published: February 08, 2023
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.
Journal: Cell reports
Published: January 19, 2023
Last Updated: 09/26/2026